369 related articles for article (PubMed ID: 17565668)
21. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
22. Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany.
Schulte B; Schmidt CS; Strada L; Götzke C; Hiller P; Fischer B; Reimer J
Int J Drug Policy; 2016 Mar; 29():57-65. PubMed ID: 26818083
[TBL] [Abstract][Full Text] [Related]
23. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial.
Soyka M; Lieb M; Kagerer S; Zingg C; Koller G; Lehnert P; Limmer C; Kuefner H; Hennig-Fast K
J Clin Psychopharmacol; 2008 Dec; 28(6):699-703. PubMed ID: 19011441
[TBL] [Abstract][Full Text] [Related]
24. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
25. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
Johnson B; Richert T
Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
[TBL] [Abstract][Full Text] [Related]
26. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial.
Soyka M; Hock B; Kagerer S; Lehnert R; Limmer C; Kuefner H
J Clin Psychopharmacol; 2005 Oct; 25(5):490-3. PubMed ID: 16160628
[TBL] [Abstract][Full Text] [Related]
27. Deficits in social perception in opioid maintenance patients, abstinent opioid users and non-opioid users.
McDonald S; Darke S; Kaye S; Torok M
Addiction; 2013 Mar; 108(3):566-74. PubMed ID: 23164063
[TBL] [Abstract][Full Text] [Related]
28. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
29. A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
Kelty E; Hulse G
Drugs; 2017 Jul; 77(11):1199-1210. PubMed ID: 28536980
[TBL] [Abstract][Full Text] [Related]
30. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
31. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
Debelak K; Morrone WR; O'Grady KE; Jones HE
Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867
[TBL] [Abstract][Full Text] [Related]
32. Prenatal exposure to methadone or buprenorphine impairs cognitive performance in young adult rats.
Kongstorp M; Bogen IL; Stiris T; Andersen JM
Drug Alcohol Depend; 2020 Jul; 212():108008. PubMed ID: 32402939
[TBL] [Abstract][Full Text] [Related]
33. Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care.
Baschirotto C; Lehmann K; Kuhn S; Reimer J; Verthein U
J Pharmacol Sci; 2020 Sep; 144(1):9-15. PubMed ID: 32586692
[TBL] [Abstract][Full Text] [Related]
34. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
[TBL] [Abstract][Full Text] [Related]
35. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
Nielsen S; Dietze P; Lee N; Dunlop A; Taylor D
Addiction; 2007 Apr; 102(4):616-22. PubMed ID: 17286641
[TBL] [Abstract][Full Text] [Related]
36. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
[TBL] [Abstract][Full Text] [Related]
37. Comparative patterns of cognitive performance amongst opioid maintenance patients, abstinent opioid users and non-opioid users.
Darke S; McDonald S; Kaye S; Torok M
Drug Alcohol Depend; 2012 Dec; 126(3):309-15. PubMed ID: 22726911
[TBL] [Abstract][Full Text] [Related]
38. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
Johnson B; Richert T
J Psychoactive Drugs; 2014; 46(5):427-35. PubMed ID: 25364995
[TBL] [Abstract][Full Text] [Related]
39. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
Orman JS; Keating GM
Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
[TBL] [Abstract][Full Text] [Related]
40. Influence of peak and trough levels of opioid maintenance therapy on driving aptitude.
Baewert A; Gombas W; Schindler SD; Peternell-Moelzer A; Eder H; Jagsch R; Fischer G
Eur Addict Res; 2007; 13(3):127-35. PubMed ID: 17570908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
